Anti-tumor Effects and Antigen Presentation Mechanisms of Toll-like Receptor 2 (TLR2) agonist-conjugated peptide

博士 === 國防醫學院 === 生命科學研究所 === 102 === Dendritic cells (DCs) can process and present extracellular antigens on MHC class I molecules to activate cytotoxic T lymphocyte (CTL) responses through an important mechanism, antigen cross-presentation. However, toll-like receptor (TLR)-mediated cross-presentat...

Full description

Bibliographic Details
Main Authors: Kuan-Yin Shen, 沈冠印
Other Authors: Shih-Jen Liu
Format: Others
Language:en_US
Published: 2014
Online Access:http://ndltd.ncl.edu.tw/handle/02005787959422829416
id ndltd-TW-102NDMC0105039
record_format oai_dc
spelling ndltd-TW-102NDMC01050392015-10-13T23:49:48Z http://ndltd.ncl.edu.tw/handle/02005787959422829416 Anti-tumor Effects and Antigen Presentation Mechanisms of Toll-like Receptor 2 (TLR2) agonist-conjugated peptide 脂質化胜肽抗癌應用與抗原呈獻分子機制之探討 Kuan-Yin Shen 沈冠印 博士 國防醫學院 生命科學研究所 102 Dendritic cells (DCs) can process and present extracellular antigens on MHC class I molecules to activate cytotoxic T lymphocyte (CTL) responses through an important mechanism, antigen cross-presentation. However, toll-like receptor (TLR)-mediated cross-presentation of extracellular antigens by DCs remains unclear. In this study, models of synthetic di-palmitoylated peptides (Pam2IDG and Pam2EQL) explored the mechanisms of TLR2-mediated cross-presentation. We observed that TLR2 facilitated the internalization of di-palmitoylated peptides by bone marrow-derived DCs (BMDCs) via clathrin-mediated endocytosis. The immunization of di-palmitoylated peptide-pulsed BMDCs induced tumor regression through TLR2 signaling. These findings indicated that exogenous TLR2 agonist-conjugated peptide could be cross-presented to CTL. We further identified di-palmitoylated peptides-induced antigen-specific CTL responses was transporter associated with antigen processing (TAP) independent. In addition, endosomal acidification inhibitor (chloroquine) or a lysosomal degradation inhibitor (Z-FL-COCHO) could block the presentation of di-palmitoylated peptides by MHC class I molecules. The endocytosed di-palmitoylated peptide was delivered rapidly from early endosome antigen-1 (EEA1)-positive endosomes to RAS-related GTP-binding protein 7 (Rab7)-associated late endosomes compared with their non-lipidated counterparts. Furthermore, we found that the Rab7 expression co-related was up-regulated by di-palmitoylated peptide was via the TLR2/MyD88 pathway. Therefore, di-palmitoylated peptide could be cross-presented efficiently via vacuolar pathway to enhance CTL responses though TLR2 signaling. In conclusion, our data suggest that TLR2-mediated cross-presentation is through the upregulation of Rab7 and a vacuolar pathway to prime CTL responses. Shih-Jen Liu 劉士任 2014 學位論文 ; thesis 69 en_US
collection NDLTD
language en_US
format Others
sources NDLTD
description 博士 === 國防醫學院 === 生命科學研究所 === 102 === Dendritic cells (DCs) can process and present extracellular antigens on MHC class I molecules to activate cytotoxic T lymphocyte (CTL) responses through an important mechanism, antigen cross-presentation. However, toll-like receptor (TLR)-mediated cross-presentation of extracellular antigens by DCs remains unclear. In this study, models of synthetic di-palmitoylated peptides (Pam2IDG and Pam2EQL) explored the mechanisms of TLR2-mediated cross-presentation. We observed that TLR2 facilitated the internalization of di-palmitoylated peptides by bone marrow-derived DCs (BMDCs) via clathrin-mediated endocytosis. The immunization of di-palmitoylated peptide-pulsed BMDCs induced tumor regression through TLR2 signaling. These findings indicated that exogenous TLR2 agonist-conjugated peptide could be cross-presented to CTL. We further identified di-palmitoylated peptides-induced antigen-specific CTL responses was transporter associated with antigen processing (TAP) independent. In addition, endosomal acidification inhibitor (chloroquine) or a lysosomal degradation inhibitor (Z-FL-COCHO) could block the presentation of di-palmitoylated peptides by MHC class I molecules. The endocytosed di-palmitoylated peptide was delivered rapidly from early endosome antigen-1 (EEA1)-positive endosomes to RAS-related GTP-binding protein 7 (Rab7)-associated late endosomes compared with their non-lipidated counterparts. Furthermore, we found that the Rab7 expression co-related was up-regulated by di-palmitoylated peptide was via the TLR2/MyD88 pathway. Therefore, di-palmitoylated peptide could be cross-presented efficiently via vacuolar pathway to enhance CTL responses though TLR2 signaling. In conclusion, our data suggest that TLR2-mediated cross-presentation is through the upregulation of Rab7 and a vacuolar pathway to prime CTL responses.
author2 Shih-Jen Liu
author_facet Shih-Jen Liu
Kuan-Yin Shen
沈冠印
author Kuan-Yin Shen
沈冠印
spellingShingle Kuan-Yin Shen
沈冠印
Anti-tumor Effects and Antigen Presentation Mechanisms of Toll-like Receptor 2 (TLR2) agonist-conjugated peptide
author_sort Kuan-Yin Shen
title Anti-tumor Effects and Antigen Presentation Mechanisms of Toll-like Receptor 2 (TLR2) agonist-conjugated peptide
title_short Anti-tumor Effects and Antigen Presentation Mechanisms of Toll-like Receptor 2 (TLR2) agonist-conjugated peptide
title_full Anti-tumor Effects and Antigen Presentation Mechanisms of Toll-like Receptor 2 (TLR2) agonist-conjugated peptide
title_fullStr Anti-tumor Effects and Antigen Presentation Mechanisms of Toll-like Receptor 2 (TLR2) agonist-conjugated peptide
title_full_unstemmed Anti-tumor Effects and Antigen Presentation Mechanisms of Toll-like Receptor 2 (TLR2) agonist-conjugated peptide
title_sort anti-tumor effects and antigen presentation mechanisms of toll-like receptor 2 (tlr2) agonist-conjugated peptide
publishDate 2014
url http://ndltd.ncl.edu.tw/handle/02005787959422829416
work_keys_str_mv AT kuanyinshen antitumoreffectsandantigenpresentationmechanismsoftolllikereceptor2tlr2agonistconjugatedpeptide
AT chénguānyìn antitumoreffectsandantigenpresentationmechanismsoftolllikereceptor2tlr2agonistconjugatedpeptide
AT kuanyinshen zhīzhìhuàshèngtàikàngáiyīngyòngyǔkàngyuánchéngxiànfēnzijīzhìzhītàntǎo
AT chénguānyìn zhīzhìhuàshèngtàikàngáiyīngyòngyǔkàngyuánchéngxiànfēnzijīzhìzhītàntǎo
_version_ 1718087278565261312